Fighting HIV on multiple fronts might lead to vaccine

September 20, 2017 by Dennis Thompson, Healthday Reporter

A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies.

Two separate research groups completely protected their own sets of lab monkeys from HIV infection using this combination vaccination strategy, albeit in two very different ways.

One group inoculated their monkeys with a "cocktail" of two HIV , while the other group genetically engineered a single antibody capable of attacking HIV in three different ways.

There's just one downside: Because these antibodies are injected into the body rather than naturally created by the immune system, people will have to receive shots on a regular basis to retain their protection against the AIDS-causing virus.

The strategy focuses on broadly neutralizing HIV antibodies, a type of antibody that attaches to the virus and prevents it from entering the immune cells that it targets, said Dr. Gary Nabel, chief scientific officer of the pharmaceutical firm Sanofi.

Previous studies have investigated using individual antibodies to block HIV, but without success, said Rowena Johnston, vice president and director of research for amfAR, the Foundation for AIDS Research.

"The virus is just so good at mutating away from any single thing we throw at it," Johnston said. "When we treat HIV, you can't give a single antiretroviral drug. You have to give a combination of at least two and optimally three. They are now also looking at this idea for antibodies."

Researchers also are looking into "" as a way to deliver these protective antibodies, as an alternative to traditional vaccination, Johnston said. The human immune system has not been capable of learning a vaccine-prompted immune response that provides continued protection against rapidly mutating HIV.

"With a vaccine, you're upping the ante in terms of complexity because you're asking the immune system to design the antibodies you want," she said. "With passive immunization, you simply administer those antibodies and you don't need to ask the immune system to develop them."

One research team tested this new strategy by injecting lab monkeys with two antibodies that block HIV by attaching to different targets located on the virus.

The researchers then tested the cocktail's effectiveness by exposing the monkeys to two strains of HIV. Each was vulnerable to one of the antibodies, but not the other.

Monkeys that received either of the antibodies individually became infected when exposed to both strains of HIV, researchers reported. However, when they received the two-antibody cocktail, they were protected against both HIV strains.

"If the virus has resistance mutations to one of the antibodies, then you really need more than one to protect," said lead researcher Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston.

Researchers from the other team took things a step further: They genetically designed a single antibody that acts as three antibodies, attacking three separate targets on HIV.

"The problem is if you take any one antibody and you use that as your umbrella to protect against infection, the virus is going to find a way to poke a hole in your umbrella and leak through and become resistant to that antibody," said Nabel, lead researcher for the effort.

"We've actually said, okay, if you poke a hole in my umbrella, I'm going to have two layers beneath it. If a virus gets through, it's going to be really unlikely to get through the second layer, and even if they get through that, there's still a third layer," Nabel continued.

All monkeys given the triple combination from the single antibody were fully protected from the , researchers reported.

Unfortunately, all these antibodies provide fleeting protection because they eventually die off and are not naturally replaced by the immune system.

"If you were going to use these in clinical practice to prevent HIV infection, you would have to repeatedly administer them," perhaps as often as every several weeks, Johnston said.

Efforts are underway to extend the life span of these antibodies, so they could provide several months of protection, Barouch said.

Barouch said his team is launching human clinical trials for its cocktail approach. Nabel's team is also working toward human trials.

Often, however, results of animal trials aren't replicated in human studies.

The studies were published Sept. 20 in the journals Science and Science Translational Medicine.

Explore further: Three-in-one antibody protects monkeys from HIV-like virus

More information: Boris Julg et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aao4235

L. Xu el al., "Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques," Science (2017). … 1126/science.aan8630

Related Stories

Three-in-one antibody protects monkeys from HIV-like virus

September 20, 2017
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers ...

Researchers find alternative pathways to HIV antibodies

May 4, 2016
The immune system appears to hamper an investigational vaccine from inducing antibodies that protect against HIV infection, but there may be ways to overcome this impediment, according to research led by the Duke Human Vaccine ...

Researchers uncover clues about how HIV virus mutates

June 1, 2017
A new study published in Cell Host & Microbe led by researchers at Fred Hutchinson Cancer Research Center completely maps all mutations that help the HIV virus evolve away from a single broadly neutralizing antibody, known ...

Antibody shields monkeys from HIV-like virus for months

April 27, 2016
Just one shot of a lab-produced antibody protected macaques against a sort of monkey HIV for nearly six months, said a study Wednesday into a potential vaccine alternative.

Patient with unique antibodies helps researchers develop strongest HIV-attacking antibody to date

January 30, 2017
(Medical Xpress)—A large international team of researchers has created what they are describing as the most powerful HIV-attacking antibody ever made. In their paper published in the journal Science Immunology, the team ...

Antibody combination puts HIV on the ropes

January 25, 2017
Without antiretroviral drug treatment, the majority of people infected with HIV ultimately develop AIDS, as the virus changes and evolves beyond the body's ability to control it. But a small group of infected individuals—called ...

Recommended for you

Details of HIV-1 structure open door for potential therapies

August 9, 2018
New research provides details of how the structure of the HIV-1 virus is assembled, findings that offer potential new targets for treatment.

Researchers uncover potential new drug targets in the fight against HIV

August 7, 2018
Johns Hopkins scientists report they have identified two potential new drug targets for the treatment of HIV. The finding is from results of a small, preliminary study of 19 people infected with both HIV—the virus that ...

Naltrexone helps HIV positive individuals reduce heavy alcohol use

August 7, 2018
Extended-release naltrexone—an injection that decreases heavy drinking in the general population when taken in conjunction with counseling—appears to help HIV-positive individuals reduce their number of heavy drinking ...

EU door opens for generic version of AIDS medicine Truvada

July 26, 2018
Patient associations on Thursday lauded an EU decision to allow the sale of generic versions of Truvada, an anti-retroviral medicine used by those diagnosed HIV-positive, the virus causing AIDS.

First randomised trial of 'kick and kill' approach to HIV cure leaves puzzles to be solved

July 24, 2018
Researchers have reported the results of the first randomised clinical trial to test a novel strategy involving waking up and then killing the 'sleeping' HIV that is hiding in the body using an experimental approach known ...

Scientists report setbacks in quest for AIDS cure

July 24, 2018
Scientists reported setbacks Tuesday in the quest for an AIDS cure, and highlighted concerns about inconclusive evidence linking a promising new HIV drug to birth defects.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.